Merck's Thinning Management
MARTIN J. WYGOD
Sold Medco to Merck for $6.6 billion last year. Felt he had Vagelos' backing but quit the race--and then Merck--because it demanded a "total commitment" he couldn't provide. A long shot with the board anyway.
JOHN L. ZABRISKIE
Merck's head of manufacturing left in December for the top job at rival Upjohn. A lifer at Merck, he seemed to have all the right credentials--but had been passed over when Markham was chosen president.
RICHARD J. MARKHAM
Elevated in late 1992 to president and heir apparent by Vagelos, he quit the job, citing personal reasons, after only seven months. The hard-charging sales executive, then 42, became president at Marion Merrell Dow.
...And other important players may follow
JUDY C. LEWENT
Merck's chief financial officer was widely rumored to be presidential timber. She will be courted intensely by headhunters, and could jump for the right opportunity--maybe back to Wall Street.
EDWARD M. SCOLNICK
The brilliant head of R&D was seen by many as Roy Vagelos' natural successor--until his gruff ways called his personnel skills into question. He may want to stay on until drugs developed during his watch debut.
JERRY T. JACKSON
Merck's worldwide sales head got a hefty golden handcuffs deal after Wygod took over much of the sales force. Jackson will likely be on headhunters' short lists, though he talks longingly of retiring to Texas.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.